A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Abstract Text:

John D Shaughnessy,Fenghuang Zhan,Bart E Burington,Yongsheng Huang,Simona Colla,Ichiro Hanamura,James P Stewart,Bob Kordsmeier,Christopher Randolph,David R Williams,Yan Xiao,Hongwei Xu,Joshua Epstein,Elias Anaissie,Somashekar G Krishna,Michele Cottler-Fox,Klaus Hollmig,Abid Mohiuddin,Mauricio Pineda-Roman,Guido Tricot,Frits van Rhee,Jeffrey Sawyer,Yazan Alsayed,Ronald Walker,Maurizio Zangari,John Crowley,Bart Barlogie,

To molecularly define high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols. Using log-rank tests of expression quartiles, 70 genes, 30% mapping to chromosome 1 (P < .001), were linked to early disease-related death. Importantly, most up-regulated genes mapped to chromosome 1q, and down-regulated genes mapped to chromosome 1p. The ratio of mean expression levels of up-regulated to down-regulated genes defined a high-risk score present in 13% of patients with shorter durations of complete remission, event-free survival, and overall survival (training set: hazard ratio [HR], 5.16; P < .001; test cohort: HR, 4.75; P < .001). The high-risk score also was an independent predictor of outcome endpoints in multivariate analysis (P < .001) that included the International Staging System and high-risk translocations. In a comparison of paired baseline and relapse samples, the high-risk score frequency rose to 76% at relapse and predicted short postrelapse survival (P < .05). Multivariate discriminant analysis revealed that a 17-gene subset could predict outcome as well as the 70-gene model. Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Publishing Authors By Initials

JD Shaughnessy,F Zhan,BE Burington,Y Huang,S Colla,I Hanamura,JP Stewart,B Kordsmeier,C Randolph,DR Williams,Y Xiao,H Xu,J Epstein,E Anaissie,SG Krishna,M Cottler-Fox,K Hollmig,A Mohiuddin,M Pineda-Roman,G Tricot,F van Rhee,J Sawyer,Y Alsayed,R Walker,M Zangari,J Crowley,B Barlogie,

For similar investigative techniques: epidemiologic methods: data collection: vital statistics: mortality: survival rate research abstracts see: investigative techniques: epidemiologic methods: data collection: vital statistics: mortality: survival rate research

PUBMED ID PMID:

MEDLINE DATE:

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Blood

VOLUME: 109

Page Numbers: 2276-84

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 14

MONTH: 11

YEAR: 2006

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Keywords Mesh Terms:

KEYWORDS: Survival Rate

MESH TERMS: pathology

Chemical & Substance for Abstract: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

AFFILIATION: Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. shaughnessyjohn@uams.edu

Country: United States

AGENCY: United States NCI

GRANT: CA97513

ACRONYM: CA

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Related Publications

• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
• Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
• Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma.
• Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
• First thalidomide clinical trial in multiple myeloma: a decade.
• High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
• Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness.
• Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
• VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.